Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024 16:05 ET
|
Annexon Biosciences
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024 08:00 ET
|
Annexon Biosciences
BRISBANE, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with...
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
March 26, 2024 16:05 ET
|
Annexon Biosciences
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024,...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 18, 2024 16:05 ET
|
Annexon Biosciences
BRISBANE, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Biosciences to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024 08:00 ET
|
Annexon Biosciences
BRISBANE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon to Host Virtual R&D Day on Guillain-Barré Syndrome, Focusing on its Serious Unmet Need and Annexon’s Novel Therapeutic Approach
February 21, 2024 08:00 ET
|
Annexon Biosciences
Virtual event on Friday, March 1, 2024 at 10:00 AM ET Event will feature GBS experts Lisa Butler of the GBS|CIDP Foundation International, Hugh Willison, MBBS, PhD, Professor Emeritus of Neurology of...
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
February 20, 2024 16:05 ET
|
Annexon Biosciences
BRISBANE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative Diseases
January 07, 2024 20:00 ET
|
Annexon Biosciences
ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in the U.S. ANX007 Global Pivotal Program in...
Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 27, 2023 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX) a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living...
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
December 20, 2023 17:27 ET
|
Annexon Biosciences
BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...